APVO Aptevo Therapeutics

Aptevo Therapeutics to Present at the Ladenburg Thalmann 2018 Healthcare Conference

Aptevo Therapeutics to Present at the Ladenburg Thalmann 2018 Healthcare Conference

SEATTLE, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that management will be presenting at the Ladenburg Thalmann 2018 Healthcare Conference on Tuesday, October 2, 2018 at 9:00 a.m. ET in Track 3, St. Germain II Ballroom in the Sofitel New York, New York City.

A live audio webcast of the presentation can be accessed at under the ‘Investors’ section of the website, under ‘Events.’  An audio reply of the webcast will be available following the live webcast.

About Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on novel oncology and hematology therapeutics to meaningfully improve patients’ lives.  Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer or autoimmune diseases.  Aptevo has two ADAPTIR antibody candidates currently in clinical development and a broad pipeline of novel investigational-stage bispecific antibody candidates focused in immuno-oncology and autoimmune disease and inflammation. For more information, please visit .

Source:

Aptevo Therapeutics

Stacey Jurchison

Senior Director, Investor Relations and Corporate Communications

206-859-6628

EN
25/09/2018

Underlying

APVOAptevo Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aptevo Therapeutics

Free Trial
APVO Aptevo Therapeu...

Aptevo Therapeutics Inc: 1 director

A director at Aptevo Therapeutics Inc bought 13,513 shares at 1.490USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...

APVO APTEVO THERAPEUTICS
11/13/25 November 13, 2025 1 EN
 PRESS RELEASE
Free
APVO Aptevo Therapeu...

Aptevo Therapeutics Receives Orphan Drug Designation for APVO436 for t...

Aptevo Therapeutics Receives Orphan Drug Designation for APVO436 for the Treatment of Acute Myelogenous Leukemia SEATTLE, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to APVO436, a bispecific antibody candidate intended for the treatment of acute myelogenous leukemia (AML). APVO436 is currently being evaluated in a Phase 1/1b clinical trial in patients with AML a...

December 6, 2019 1 EN
 PRESS RELEASE
Free
APVO Aptevo Therapeu...

Aptevo Therapeutics and Alligator Bioscience Present New Preclinical D...

Aptevo Therapeutics and Alligator Bioscience Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer 2019 Annual Meeting Preclinical Data Show That ALG.APV-527 is Well Tolerated with Repeated Dosing Preliminary in vivo Data Show that ALG.APV-527 has Potent Anti-tumor Activity and Induces an Immunological Memory Response SEATTLE and LUND, Sweden, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel immuno-oncology and hematology therapeutics and Alligator Bioscience AB (Nasdaq Stock...

November 8, 2019 1 EN
 PRESS RELEASE
Free
APVO Aptevo Therapeu...

Aptevo Therapeutics Reports Third Quarter 2019 Financial Results

Aptevo Therapeutics Reports Third Quarter 2019 Financial Results Reports Record Net Revenue for IXINITY; Achieves 55% Increase in Year-over-Year Quarterly Net Revenue Advances APVO436 Phase 1/1b Clinical Study in AML/MDS SEATTLE, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today provided a business review and reported its financial results for the third quarter ended September 30, 2019. “Net revenue for IXINITY® in the third quarter of 2019 reached a record level a...

November 7, 2019 1 EN
 PRESS RELEASE
Free
APVO Aptevo Therapeu...

Aptevo Therapeutics Provides Corporate and Pipeline Update

Aptevo Therapeutics Provides Corporate and Pipeline Update Reports Record Quarterly IXINITY® Net Revenue and New Patient Conversions Following Launch of New 3,000 IU Assay Provides Update on Ongoing APVO436 Phase 1/1b Clinical Study;Evidence of Potential Clinical Activity Emerging;No Dose-Limiting Toxicities or Anti-drug Antibodies Observed to Date in the Study Reports Decision to Discontinue Development of APVO210 Announces Expense Reduction Plan to Reduce Annual Cash Burn by Approximately 30% Management to Host Conference Call Today at 5:00 p.m. E.T./2:00 p.m. P.T. ...

October 3, 2019 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch